FMP-825

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameFMP-825

Drug Alias Nameanti-obesity agent (MDI)obesity therapeutics (MDI)beta-3 adrenoceptor agonist (Molecular Design International)beta-3 adrenoceptor agonists (MDI)FMP-825

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionBeta-3 adrenergic receptor agonists

TargetsBeta-3 adrenergic receptor

Therapy Area/IndicationsObesityDiabetes Mellitus

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMolecular Design International

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMolecular Design International

Active IndicationsN/A

Inactive IndicationsObesityDiabetes Mellitus

Other Information

ATC CodeN/A